Petros Pharmaceuticals Inc (PTPI): Price-to-Sales Ratio

Corporate company logo of Petros (PTPI)

The normalized P/S ratio of Petros Pharmaceuticals (PTPI) reflects the market valuation of Petros Pharmaceuticals, where the 0.20 mark characterizes this parameter. This trend is driven by the availability of over-the-counter drugs and the cost of components. Stability is maintained through the full localization of US logistics. Simultaneously, the business is implementing eco-friendly packaging and reducing its carbon footprint, ensuring high occupational safety standards.

PTPI Petros Pharma Market Cap to Revenue (07/04/2022 - 06/28/2025)

Metric breakdowns and analytics for Petros Pharmaceuticals Inc (PTPI)

- share price and consensus valuation forecast:
Price Performance Chart Petros Pharmaceuticals Inc|PTPI - Price Target Chart
- stock exchange capitalization data:
Market Valuation Petros Pharma|PTPI - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Petros Pharmaceuticals|PTPI - Company Net Assets|Market Cap to Book Value Multiple petrospharma.com|PTPI - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Petros Pharmaceuticals|PTPI - Long-Term Debt to Equity|Current Liabilities to Capital petrospharma.com|PTPI - Company Debts|Debts to Net Assets Petros Pharmaceuticals, Inc.|PTPI - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Petros Pharmaceuticals|Critical Liquidity Ratio petrospharma.com
- earnings and multiples data:
PTPI - Net Profit|Expected Net Income Petros Pharmaceuticals|PTPI - P/E Multiple|Forward P/E Multiple Petros Pharma|PTPI - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Petros Pharmaceuticals|PTPI - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Petros Pharmaceuticals|PTPI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth petrospharma.com|PTPI - Earnings growth in current year|Expected earnings per share growth for next year Petros Pharmaceuticals
- sales revenue and business income indicators:
PTPI - Revenue and Sales Volume|Company Expected Sales Volume Petros|PTPI - Market Cap to Revenue|Forward P/S Multiple Petros Pharmaceuticals, Inc.
Fundamental company analysis:PTPI, Petros
Finished products of Petros Pharmaceuticals, Inc.

Steady demand for urological drugs and insurance coverage of revenues for Petros Pharmaceuticals (PTPI) minimize the impact of market cyclicality on the business. The ratio of market capitalization to annual revenue determines the value of a single dollar of sales, helping investors find the balance between asset undervaluation and stagnation, which is clearly reflected in the P/S multiple time chart.

Who Petros Pharmaceuticals competes with

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Market Capitalization-to-Revenue Ratio BHST|Invizyne Technologies - P/S Multiple|oramed.com (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|Market Cap to Revenue Ratio HYFT|ABVC (ABVC BioPharma, Inc) - P/S Multiple|P/S Multiple cumberlandpharma.com|Price-to-Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Price-to-Revenue Multiple|P/S Multiple TELO (telomirpharma.com)|RANI - Market Cap to Revenue|SNYR - Price-to-Revenue Ratio|rallybio.com - Market Cap to Sales Volume|LEXX: P/S Multiple|Market Cap to Revenue Pulmatrix Inc|PTHL (Pheton Holdings) - P/S Multiple|Price to Sales Aptorum Group Limited APM|Price-to-Revenue Ratio Lyra Therapeutics (LYRA)|Market Cap to Revenue Impact BioMedical Inc IBO|Price-to-Revenue Ratio tnfpharma.com TNFA|Market Capitalization-to-Revenue Ratio YCBD|PainReform Ltd - P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Market Cap to Revenue|lipella.com (LIPO) - Price-to-Revenue Ratio|OptiNose (OPTN) - P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - P/S Multiple|PROC: Market Capitalization-to-Revenue Ratio|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)